Scientific instrument company Bruker (NASDAQ: BRKR). beat Wall Street’s revenue expectations in Q3 CY2025, but sales were flat year on year at $860.5 million. On the other hand, the company’s full-year revenue guidance of $3.43 billion at the midpoint came in 0.5% below analysts’ estimates. Its non-GAAP profit of $0.45 per share was 37.3% above analysts’ consensus estimates.

Is now the time to buy BRKR? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

Bruker’s third quarter results were marked by flat revenue compared to last year, but the company exceeded Wall Street’s expectations for both sales and non-GAAP profit. Management highlighted a rebound in bookings, particularly in academic and government markets outside the U.S., as well as improving orders from the biopharma and applied segments. CEO Frank Laukien noted, “Our Q3 performance was quite a bit better than expected and represents a meaningful sequential step-up from our Q2 performance.” Despite ongoing headwinds from weak demand and tough comparisons, management’s commentary remained focused on sequential improvement and emerging positive order trends.

Looking ahead, Bruker’s updated guidance reflects cautious optimism, with management pointing to recent order momentum as a potential turning point for demand in 2026. The company is prioritizing significant cost-saving initiatives, aiming for $100–$120 million in annual reductions to drive margin expansion and double-digit non-GAAP EPS growth next year. CFO Gerald Herman stated, “We are fully committed to significant margin expansion and double-digit EPS growth in fiscal year '26,” while CEO Frank Laukien cautioned that forward visibility hinges on fourth-quarter order flow and government funding trends, especially in research markets.

Key Insights from Management’s Remarks

Management attributed the quarter’s outcomes to improved international orders, product momentum in diagnostics, and ongoing cost-saving initiatives, while noting that late timing of orders limited immediate revenue impact.

• Order strength outside U.S.: Robust bookings growth in academic and government markets was driven primarily by Europe, Japan, and China, offsetting continued softness in the U.S.
• Diagnostics and applied markets: Microbiology and infectious disease diagnostics, particularly the MALDI Biotyper and ELITech molecular diagnostics, saw strong demand, with ELITech placements outpacing business plans and expected to generate multi-year consumable revenue.
• Biopharma and spatial biology: Biopharma orders improved, especially in the U.S., while spatial biology and multiomics tools launched earlier in the year gained traction, supporting Bruker’s positioning in post-genomic research.
• Cost-saving initiatives on track: Bruker’s Project Accelerate 2.0 is progressing toward $100–$120 million in cost reductions, with over 90% of actions implemented, targeting meaningful margin expansion in 2026.
• Tariffs and currency headwinds: New tariffs and foreign exchange pressures contributed to the year-over-year margin decline, with management emphasizing operational adjustments to partially mitigate these impacts.

Drivers of Future Performance

Bruker's outlook for the next year centers on order momentum, cost reduction efforts, and stabilization in end markets, with execution risk tied to macroeconomic and funding uncertainties.

• Cost savings drive margins: Management expects the majority of $100–$120 million in annual cost reductions to be realized in 2026, aiming for substantial non-GAAP operating margin expansion even in a flat revenue scenario.
• Order visibility and research funding: Forward performance will depend on the sustainability of recent order improvements, especially in academic and government markets, where U.S. government funding levels and timing of grant dispersals remain uncertain.
• Geopolitical and macro risks: Management highlighted ongoing risks from tariffs, currency fluctuations, and potential delays in government budgets or shutdowns, all of which could impact both orders and revenue timing.

Catalysts in Upcoming Quarters

Going forward, our analysts will closely monitor (1) whether recent order momentum in academic and government markets translates into sustained revenue growth, (2) execution and realization of planned cost savings for margin improvement, and (3) the impact of government funding cycles and tariffs on both demand and profitability. Developments in product adoption, especially in diagnostics and spatial biology, will also be important indicators of future performance.

Bruker currently trades at $38.71, in line with $38.94 just before the earnings. Is there an opportunity in the stock?The answer lies in our full research report (it’s free for active Edge members).

High Quality Stocks for All Market Conditions

Trump’s April 2025 tariff bombshell triggered a massive market selloff, but stocks have since staged an impressive recovery, leaving those who panic sold on the sidelines.

Take advantage of the rebound by checking out our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.